Predictive factors of pathologic complete response and clinical tumor progression after preoperative chemotherapy in patients with stage II and III breast cancer

Investigational New Drugs

Volumn 30, Issue 1, 2012, Pages 408-416

  Jeong, Jae Heon ^a   Jung, So Youn ^a   Park, In Hae ^a   Lee, Keun Seok ^a   Kang, Han Sung ^a   Kim, Seok Won ^a   Kwon, Youngmee ^a   Kim, Eun A ^a   Ko, Kyung Lan ^a   Nam, Byung Ho ^a   Lee, Seeyoun ^a   Ro, Jungsil ^a  

^a National Cancer Center   (South Korea)

Author keywords

Breast cancer; Pathologic complete response; Predictive factor; Preoperative chemotherapy

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CANCER STAGING; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PREDICTION; PREMENOPAUSE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; CHI-SQUARE DISTRIBUTION; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DEOXYCYTIDINE; DOXORUBICIN; FEMALE; FLUOROURACIL; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LOGISTIC MODELS; MASTECTOMY; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; NEOPLASM STAGING; ODDS RATIO; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TAXOIDS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84856559623     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9555-7     Document Type: Article

References (22)

1. Lee KS, Ro J, Nam B et al (2008) A randomized phase-III trial of docetaxel/capecitabine versus doxorubicin/cyclophosphamide as primary chemotherapy for patients with stage II/III breast cancer. Breast Cancer Res Treat 109:481-489 (Pubitemid 351692059)
2. Lee KS, Ro J, Lee ES, Kang HS, Kim SW, Nam BH, Kwon Y, Kim EA, Shin KH (2009) Primary systemic therapy with intermittent weekly paclitaxel plus gemcitabine in patients with stage II and III breast cancer: A phase II trial. Invest New Drugs. doi:10.1007/s10637-009-9229-5
3. Wolff AC, Hammond ME, Schwartz JN et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-145 (Pubitemid 350003059)
4. Greene FL, Page DL, Flemming ID (2002) AJCC cancer staging manual, 6th edn. Springer, New York
5. Henson DE, Ries L, Freedman LS, Carriaga M (1991) Relationship among outcome, stage of disease, and histologic grade for 22,616 cases of breast cancer. The basis for a prognostic index. Cancer 68:2142-2149
6. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
7. De Lena M, Zucali R, Viganotti G, Valagussa P, Bonadonna G (1978) Combined chemotherapy-radiotherapy approach in locally advanced (T3b-T4) breast cancer. Cancer Chemother Pharmacol 1:53-59 (Pubitemid 9025112)
8. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B (2001) Preoperative chemotherapy in patients with operable breast cancer: Nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr:96-102
9. Cocquyt VF, Blondeel PN, Depypere HT et al (2003) Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma. Eur J Surg Oncol 29:361-367 (Pubitemid 36675693)
10. Mathieu MC, Rouzier R, Llombart-Cussac A, Sideris L, Koscielny S, Travagli JP, Contesso G, Delaloge S, Spielmann M (2004) The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile. Eur J Cancer 40:342-351 (Pubitemid 38121270)
11. Cristofanilli M, Gonzalez-Angulo A, Sneige N et al (2005) Invasive lobular carcinoma classic type: Response to primary chemotherapy and survival outcomes. J Clin Oncol 23:41-48 (Pubitemid 41702621)
12. Rouzier R, Perou CM, Symmans WF et al (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11:5678-5685. doi:10.1158/1078-0432. CCR-04-2421 (Pubitemid 41170290)
13. Bear HD, Anderson S, Smith RE et al (2006) Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B- 27. J Clin Oncol 24:2019-2027. doi:10.1200/JCO.2005.04.1665 (Pubitemid 46622110)
14. Gianni L, Baselga J, Eiermann W et al (2005) Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clin Cancer Res 11:8715-8721. doi:10.1158/1078-0432.CCR-05-0539 (Pubitemid 43005921)
15. Guarneri V, Broglio K, Kau SW et al (2006) Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 24:1037-1044. doi:10.1200/JCO.2005.02. 6914 (Pubitemid 46638799)
16. Ring AE, Smith IE, Ashley S, Fulford LG, Lakhani SR (2004) Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br J Cancer 91:2012-2017. doi:10.1038/sj. bjc.6602235 (Pubitemid 40128767)
17. von Minckwitz G, Blohmer JU, Raab G et al (2005) In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: The GEPARTRIO pilot study. Ann Oncol 16:56-63. doi:10.1093/annonc/mdi001 (Pubitemid 40124479)
18. von Minckwitz G, Raab G, Caputo A et al (2005) Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: The GEPARDUO study of the German Breast Group. J Clin Oncol 23:2676-2685. doi:10.1200/JCO.2005.05.078 (Pubitemid 46179457)
19. Prisack H, Karreman C, Modlich O, Audretsch W, Danae M, Rezai M, Bojar H (2005) Predictive biological markers for response of invasive breast cancer to anthracycline/cyclophosphamide- based primary (radio-)chemotherapy. Anticancer Res 25:4615-4621 (Pubitemid 41729522)
20. Caudle AS, Gonzalez-Angulo AM, Hunt KK et al (2010) Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28:1821-1828. doi:10.1200/ jco.2009.25.3286
21. Cuppone F, Bria E, Carlini P et al (2008) Taxanes as primary chemotherapy for early breast cancer. Cancer 113:238-246
22. Ko SS (2008) Chronological changing patterns of clinical characteristics of Korean breast cancer patients during 10 years (1996-2006) using nationwide breast cancer registration on-line program: Biannual update. J Surg Oncol 98:318-323